Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-18T08:12:18.313Z Has data issue: false hasContentIssue false

Postlaunch evidence generation practices among health technology assessment bodies in Europe

Published online by Cambridge University Press:  19 April 2022

Janet Puñal-Riobóo
Affiliation:
Galician Health Knowledge Agency (AVALIA-T, ACIS), Santiago de Compostela, Spain
Leonor Varela-Lema*
Affiliation:
Preventive Medicine and Public Health Department, University of Santiago de Compostela, Santiago de Compostela, Spain
Chantal Guilhaume
Affiliation:
Haute Autorité de Santé (HAS), Saint-Denis, France
Margaret Galbraith
Affiliation:
Haute Autorité de Santé (HAS), Saint-Denis, France
Chantal Bélorgey
Affiliation:
Haute Autorité de Santé (HAS), Saint-Denis, France
Maria José Faraldo
Affiliation:
Galician Health Knowledge Agency (AVALIA-T, ACIS), Santiago de Compostela, Spain
Amélie Meillassoux
Affiliation:
Haute Autorité de Santé (HAS), Saint-Denis, France
*
*Author for correspondence: Leonor Varela-Lema, E-mail: leonor.varela@usc.es
Rights & Permissions [Opens in a new window]

Abstract

Objectives

The term Postlaunch Evidence Generation (PLEG) refers to evidence generated after the launch or licensing of a health technology. The aim of this paper is to provide an overview of the implementation of these practices in the European Union in order to explore cross-border cooperation opportunities.

Methods

In December 2019, a survey composed of nine closed-ended questions with multiple choice answers about the PLEG practices in each country was sent to all twenty-five dedicated work package (WP5B) partners of the European Network of Health Technology Assessment (EUnetHTA) Joint Action 3. In addition to the survey, the national practices were discussed during a face-to-face meeting with WP5B partners.

Results

Twelve Health TechnologyAssessment (HTA) bodies completed the survey. Of these, eleven reported procedures in place for official requests for PLEGs in their remit. In the large majority of cases, the requests are made at the time of the assessment/appraisal. Several agencies participate in the definition of the scope of the PLEG or review of its protocol. Data collection and analysis mainly lie with companies for pharmaceuticals, whereas it is more the responsibility of the HTA bodies for medical devices. Only one agency owns the data and is able to exchange them without asking permission.

Conclusions

Most agencies recommend European collaboration on PLEG commence once the evidence gaps have been defined or during the production of the HTA report in the case of European joint assessment.

Information

Type
Article Commentary
Copyright
© The Author(s), 2022. Published by Cambridge University Press
Figure 0

Table 1.JA3 WP5B—Questionnaire on PLEG practices

Figure 1

Table 2.Agencies Who Participated in the Survey